Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Perfusion
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Smith, C. W
Right arrow Articles by Webb, D. P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, C. W
Right arrow Articles by Webb, D. P
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ACETYLSALICYLIC ACID
Medline Plus Health Information
*Blood Thinners
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Quality assessment of platelet rich plasma during anti-platelet therapy

Chad W Smith

Tennessee Perfusion Services, PLLC, Centennial Medical Center, Cardiothoracic Surgery, Nashville, Tennessee, USA, Graduate Degree Completion Program, School of Allied Health Professions, University of Nebraska Medical Center, Omaha, Nebraska, USA, Chadsmail{at}comcast.net

Robert S Binford

Centennial Medical Center, Cardiothoracic Surgery, Nashville, Tennessee, USA

David W Holt

Program Director Graduate Degree Completion, School of Allied Health Professions, University of Nebraska Medical Center, Omaha, Nebraska, USA

David P Webb

Director of Perfusion Services, Vanderbilt Medical Center, Nashville, Tennessee, USA

Platelet rich plasma (PRP) is being used with increased frequency in many surgical procedures for its known benefits of accelerated surgical wound site healing. Speculations in its efficacy in the presence of anti-platelet therapy have been proposed. To aid in defining a quality platelet rich plasma product in the presence of acetylsalicylic acid (ASA) and Plavix (clopidogrel bisulfate), we investigated three (3) groups (n=18) of cardiac surgical patients receiving PRP. Platelet function test, platelet concentration, and quantification of growth factors (PDGF-bb and TGF-b1) were evaluated. Results showed no statistical evidence of decreased growth factors delivered to the surgical wound site in the presence of acetylsalicylic acid (ASA) and/or Plavix (clopidogrel bisulfate). Evidence in this pilot study supports the use of PRP for patients receiving Plavix and aspirin therapy without compromising the quantity of specific growth factors delivered to a wound site. Perfusion (2007) 22, 41—50.

Key Words: Platelet Rich Plasma • Plavix • Aspirin • PDGF-bb • TGF-b1

Perfusion, Vol. 22, No. 1, 41-50 (2007)
DOI: 10.1177/0267659107077950
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?